Restoring blood coagulation in patients
taking Factor Xa Direct Oral Anticoagulants
(FXa-DOACs)
Our focus lies in the development of a breakthrough, swift-acting, and convenient universal bypassing agent that restores blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).
We aim to stop severe bleeding and eliminate bleeding risk during surgery in patients taking FXa DOACs.
VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs
News & events
- Conferences & Events
Episode of The BioHub Podcast featuring our Chief Operating Officer Martijn Negen. In Q4 2025, VarmX signed a strategic collaboration...
- News
VarmX and Rentschler Biopharma expand collaboration from early development to late‑stage and commercial manufacturing of VMX-C001 VMX‑C001 builds on strong...